FoxM1 transactivates PTTG1 and promotes colorectal cancer cell migration and invasion. by Zheng, Yun et al.
UCLA
UCLA Previously Published Works
Title
FoxM1 transactivates PTTG1 and promotes colorectal cancer cell migration and invasion.
Permalink
https://escholarship.org/uc/item/52q7f02n
Journal
BMC medical genomics, 8(1)
ISSN
1755-8794
Authors
Zheng, Yun
Guo, Jinjun
Zhou, Jin
et al.
Publication Date
2015-08-12
DOI
10.1186/s12920-015-0126-9
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
RESEARCH ARTICLE Open Access
FoxM1 transactivates PTTG1 and promotes
colorectal cancer cell migration and invasion
Yun Zheng1,2†, Jinjun Guo1,3†, Jin Zhou4, Jinjian Lu5, Qi Chen1, Cui Zhang6, Chen Qing7, H. Philip Koeffler1
and Yunguang Tong1,6*
Abstract
Background: Metastasis is the major cause of cancer-related death. Forkhead Box M1 (FoxM1) is a master
regulator of tumor metastasis. This study aims to identify new FoxM1 targets in regulating tumor metastasis
using bioinformatics tools as well as biological experiments.
Methods: Illumina microarray was used to profile WT and PTTG1 knockout HCT116 cells. R2 Genomics Analysis
was used to identify PTTG1 as a potential FoxM1 targeted gene. Luciferase reporter array, EMSA and Chromatin
Immunoprecipitation (ChIP) were used to determine the binding of FoxM1 to PTTG1 promoter. Boyden chamber
assay was used to evaluate the effects of FoxM1-PTTG1 on cell migration and invasion. Splenic-injection induced
liver metastasis model was used to evaluate the effects of FoxM1-PTTG1 on liver metastasis of colorectal cancer.
Results: Analyses of multiple microarray datasets derived from human colorectal cancer indicated that
correlation levels of FoxM1 and pituitary tumor transforming gene (PTTG1) are highly concordant
(R = 0.68 ~ 0.89, p = 2.1E-226 ~ 9.6E-86). FoxM1 over-expression increased and knock-down decreased PTTG1
expression. Luciferase reporter assay identified that the −600 to −300 bp region of PTTG1 promoter is
important for FoxM1 to enhance PTTG1 promoter activity. EMSA and ChIP assays confirmed that FoxM1
directly binds to PTTG1 promoter at the −391 to −385 bp region in colorectal cancer cells. Boyden chamber
assay indicated that both FoxM1 and PTTG1 regulate migration and invasion of HCT116 and SW620 colorectal
cancer cells. Further in vivo assays indicated that PTTG1 knock out decreased the liver metastasis of FoxM1
over-expressing HCT116 cells. Microarray analyses identified 662 genes (FDR < 0.05) differentially expressed between
WT and PTTG1−/− HCT116 cells. Among them, dickkopf homolog 1 (DKK1), a known WNT pathway inhibitor, was
suppressed by PTTG1 and FoxM1.
Conclusions: PTTG1 is a FoxM1 targeted gene. FoxM1 binds to PTTG1 promoter to enhance PTTG1 transcription, and
FoxM1-PTTG1 pathway promotes colorectal cancer migration and invasion.
Background
Colorectal cancer (CRC) is the third most commonly
diagnosed cancer and the second leading cause of
cancer-related death in the United States. Almost a third
of CRC patients have metastatic disease at diagnosis [1].
Half of the patients diagnosed and resected with early-
stage disease subsequently develop metastasis [2]. The
process of cancer metastasis consists of a series of
sequential and interrelated steps, including invasion,
detachment from the primary sites, intravasation, sur-
vival in the circulation and translocation to microves-
sels of target organs, extravasation and colonization [3].
Several pathways, including Cadherin-catenin system,
integrins, matrix metalloproteinases (MMPs), epider-
mal growth factor receptor (EGFR) signaling pathways
(including the RAS-RAF-MAPK and PI3K/AKT), and
the c-Met and hepatocyte growth factor/scatter factor
(HGF/SF) signaling cascade (including the Wnt
pathway, the Ras pathway and the PI3K/AKT pathway)
have shown being involved in the CRC metastasis
[4–9]. However, we still know very little about the exact
molecular mechanisms that regulate CRC metastasis.
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Pituitary tumor-transforming gene-1 (PTTG1) was
isolated from rat pituitary tumor cells in 1997 [10]. As a
vertebrate securin, PTTG1 functions in cell replication,
cell cycle control, DNA damage/repair, organ develop-
ment, metabolism, cell transformation and cell senes-
cence [11, 12]. And more importantly, PTTG1 is highly
expressed in tumors derived from a variety of organs,
including colon, pituitary, thyroid, breast, ovary, uterine,
lung and esophagus [13–19]. PTTG1 has been identified
as a key signature gene associated with tumor metasta-
sis. PTTG1 activates c-Myc and cyclin D3 (CCND3) to
facilitate cell proliferation, increases basic fibroblast growth
factor (bFGF), vascular endothelial growth factor (VEGF)
and matrix metalloproteinase 2 (MMP2) expression to
induce angiogenesis, which play an important role in tumor
development and cancer metastasis, and also induces
interleukin-8 to function in metastasis [11, 20–22]. PTTG1
interacts with transcription factors including p53, Sp1, and
upstream stimulatory factor 1 (USF1), which may induce
additional genes involved in tumorigenesis and cancer
development [20, 23, 24]. In terms of colorectal cancer,
PTTG1 overexpression is associated with tumourigenesis,
progression and cancer metastasis [25].
The human forkhead box protein M1 (FoxM1) gene,
consisting 10 exons, is mapped to chromosome 12p13-3,
and plays important roles in cellular proliferation and
differentiation during embryogenesis and development of
cancer [26–28]. FoxM1 protein has been identified as a key
regulator of cell cycle by targeting genes involved in G1/S
progression and G2/M transition such as cyclin B1,
Cdc25B, Aurora B and Polo like kinases, etc. [27]. Expres-
sion of FoxM1 is dramatically elevated in tumor cells
derived from liver, lung, colon, breast and prostate [29].
FoxM1 contributed to the development and growth of
mouse CRC [30] as well as a subset of human CRC [31].
FoxM1 is regarded as a master regulator of tumor metasta-
sis [32]. Abnormal activation of FoxM1 leads to overexpres-
sion of multiple angiogenic genes, such as MMP-2, Cav-1,
ZEB1 and ZEB2, which result in overexpression of multiple
pro-invasion and -metastasis molecules [28, 33–35].
As described above, abnormal transcription and expres-
sion of PTTG1 and FoxM1 are involved in cancer progres-
sion and metastasis. However, the precise roles of PTTG1
and FoxM1 in CRC progression and metastasis remain
unclear. In the present study, we demonstrated that FoxM1
and PTTG1 were concordantly up-regulated in colorectal
cancers. FoxM1 activates PTTG1 and promotes migration
and invasion of colorectal cancer cells.
Methods
Microarray data analyses
We used R2 Genomics Analysis and Visualization
Platform (http://r2.amc.nl) to determine the correl-
ation between FoxM1 and PTTG1 expression in seven
microarray datasets derived from tumors. Six datasets
were from Gene Expression Omnibus (GEO, http://
www.ncbi.nlm.nih.gov/gds/), including three colon
cancer datasets (GSE2109, n = 315; GSE41258, n = 388;
GSE39582, n = 564), one breast cancer dataset (GSE3494,
n = 251), one ovarian cancer dataset (GSE9891, n = 285)
and one neuroblastoma dataset (GSE45547, n = 649). One
glioma dataset (n = 403) was from TCGA. These datasets
has been processed and stored in the server of R2
platform.
To identify potential PTTG1-targeted genes, total
RNA from PTTG1+/+ and PTTG1−/− HCT116 cells was
isolated using the RNeasy Kit (Qiagen, Germantown,
MD, USA) and analyzed using Illumina microarrays
(HumanHT-12_V4). Raw data were processed using the
manufacturer’s standard protocol and further analyzed
using Partek 6.5. Microarray data have been deposited
into the GEO database (GSE58863).
Cell culture and transfections
HCT116 and SW620 cells were obtained from the
American Tissue Culture Collection (ATCC, Manassas,
VA, USA) and cultured at recommended conditions.
HCT116 PTTG+/+ and PTTG−/− cells were kindly pro-
vided by Dr Bert Vogelstein, Johns Hopkins University
(Baltimore, MD, USA). Transfections were performed
in 70–80 % confluent cells using Lipofectamine 2000
(Invitrogen, Grand Island, NY, USA) according to the
manufacturer’s protocol.
Plasmids and siRNAs
Four different human PTTG1 promoter fragments
(from-1300 to +50, from −900 to +50, from −600 to
+50 and from −300 to +50 bp ) were amplified from
human genomic DNA (Roche Company, Basel,
Switzerland) using TaKaRa LA Taq, and inserted into
the pGL3-Basic luciferase reporter vector (Promega,
Madison, WI, USA). Wild-type FoxM1 and PTTG1 ex-
pression plasmids were amplified from human FoxM1
and PTTG1 cDNA using a High-Fidelity polymerase
(Clontech, Mountain View, CA, USA) and cloned into
pcDNA3.1/myc-his vector (Invitrogen). All plasmids
above were sequenced by Sequetech (Mountain View,
CA, USA). Predesigned human PTTG1 siRNA (ID
s17655), FoxM1 siRNA (ID s5248) and negative control
No. 1 siRNA (Cat# AM4611) were obtained from Ambion
(Grand Island, NY, USA).
RNA extraction and real-time PCR
Total RNA was isolated using TRIZOL Reagent (Invitro-
gen). Three micrograms of total RNA were used to
synthesize cDNA with SuperScript II Reverse Transcript-
ase (Invitrogen). Real-time PCR was amplified in 20 μl re-
action mixtures (100 ng template, 0.5 μM of each primer,
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10 μl 2× SYBR GREEN Master Mix (Applied Biosystems,
Foster City, CA, USA) using the following parameters:
95 °C for 1 min, followed by 40 cycles of 95 °C for 20 s,
60 °C for 40 s. β-actin was used as internal control.
Sequence of real-time PCR primers were provided in
Additional file 1.
Western blot analysis
Total cell lysate was prepared in RIPA buffer (Sigma, St.
Louis, MO, USA) containing Protease Inhibitor Cocktail
(Sigma). Protein concentrations were measured by Coo-
massie Plus Assay Kit (Pierce, Rockford, IL USA) using
BSA as standard. Equal amounts (100 μg) of proteins were
separated by NuPAGE Novex Bis-Tris Gels (Invitrogen)
and transferred onto polyvinylidene difluoride (PVDF)
membrane (Millipore, Billerica, MA, USA). The mem-
brane was incubated in TBS buffer containing 5 % non-
fat dry milk (Bio-Rad, Hercules, CA, USA) for 1 hour
at room temperature, followed by incubation with the
primary antibodies at 4 °C overnight: FoxM1 (1:200),
PTTG1 (1:500) and DKK1 (1:200) were from Abcam
(Cambridge, MA, USA). β-actin (1:5000) was from Sigma.
After washes with TTBS (0.5 % Tween-20 in TBS),
membranes were subsequently incubated with horseradish
peroxidase linked secondary antibody (GE Healthcare,
Piscataway, NJ, USA) for 1 hour at room temperature and
developed using ECL Western Blotting Detection Re-
agents (GE Healthcare). Detected bands were quantified
using Image J v1.43 as instructed in the software manual.
Luciferase reporter assay
Cells were plated into 24-well plates and incubated at 37 °C
overnight. Each well was co-transfected with: 1) 200 ng
PTTG1 luciferase promoter, pGL3-Basic as control; 2)
800 ng FoxM1 expression plasmid, empty pcDNA3.1 vec-
tor as control; or 75 ng FoxM1 siRNA, negative control
No. 1 siRNA as control; 3) pRL-TK (Promega) encoding
Renilla luciferase was used as an internal control (10 ng/
well) to assess transfection efficiency. After 24 hours,
whole-cell lysates prepared with passive lysis buffer were
collected for reporter detection by the Dual Luciferase Re-
porter System (Promega) according to the manufacturer’s
protocol. Reactions were measured using an Orion Micro-
plate Luminometer (Berthold Detection System, Pforzheim,
Germany). Transfections were performed in triplicate and
repeated four times to assure reproducibility.
Electrophoresis mobility shift assay (EMSA)
Fluorescence-based Electrophoretic Mobility Shift Assay
(EMSA) Kit (Invitrogen) was used to assess binding of
FoxM1 on PTTG1 promoter. PTTG1 promoter 60 bp
fragment (ATATTTCTATTTATTTTCCATCCTTTTTA
CAGGGTCATC TAAATAAAAATATCTTAAAGC, −398
to −339 bp upstream from the human PTTG1 TSS)
was found containing two putative FoxM1 binding sites
(−391 to −385 and −359 to −353 bp). The wild type
fragment (defined as Biotin-Probe and a mutant with-
out both FoxM1 binding sites (ATATTTCgatcgtgTTT
CCATCCTTTTTACAGGGTCATCatccttgAAATATCT
TA AAGC, defined as Biotin-dmProbe), and −391 to
−385 mutant 60 bp probe (ATATTTCgatcgtgTTTCC
ATCCTTTTTACAGGGTCATCTAAATAAAAATATC
TTAAAGC, defined as 1st site mProbe) were synthe-
sized with 3’-ends labeled with biotin. The oligonucleo-
tides without biotin were used as negative control and
competitors, including wild type 60 bp probe (defined as
Cold Probe), −398 to −377 wild type 22 bp fragment
(ATATTTCTATTTATTTTCCATC, defined as 1st site
oligo) and −367 to −363 wild type 25 bp fragment
(GGGTCATC TAAATAAAAATATCTTA, defined as 2nd
site oligo). FoxM1 was overexpressed in HCT116 cells,
and nuclear protein was extracted using a nuclear extract
kit (Active Motif ). Protein concentration was measured
by Coomassie Plus Assay Kit (Pierce). Oligonucleotides
(1 μg) was incubated with 1 mg nuclear proteins for
20 min at room temperature in binding buffer containing
12 % glycerol, 12 mM HEPES (pH 7.9), 4 mM Tris
(pH 7.9), 150 mM KCl, 1 mM EDTA, 1 mM dithiothrei-
tol, and 10 μg polydeoxyinosinic deoxycytidylic acid com-
petitor. The mixtures were analyzed according to the
provided manual of the EMSA kits.
Chromatin immunoprecipitation (ChIP)
Using a ChIP kit (Active Motif, Carlsbad, CA, USA),
about 107 cells were cross-linked and lysed. Chromatin
was sheared to 300 to 700 bp fragments. Sheared chro-
matin DNA mixture (normalized inputs) was incubated
with 4 μg FoxM1 antibody (#Santa Cruz Biotechnology,
Santa Cruz, CA, USA) overnight at 4 °C. Negative
control IgG and positive control H3 antibody were
added at 10 μl (4 μg) per ChIP reaction. Real-time PCR
were amplified using PTTG1 promoter primer (targeting
−391 to −385 bp region), PTTG1 exon2 primer (as nega-
tive control) and VEGF promoter primer (as positive
control).
In vitro migration and invasion assay
Cell migration and invasion assays were performed in
6.5 mm Transwells (Corning #3422, Corning, NY, USA).
Cells (2 × 105) suspended in 100 μ l serum-free medium
were added to the upper chamber and the lower cham-
ber was filled with complete medium with 10 % serum.
Cells were allowed to migrate at 37 °C for 48 h. After
removing non-migrated cells, membranes were fixed in
methanol and stained with 0.05 % crystal violet. Migrated
cells were photographed and quantified in five random
fields per membrane. Each sample was assayed in
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triplicate. For invasion assay, the Transwells were first
coated with Matrigel and cells were allowed to invade for
72 h. For wound assay, cells were grown to confluence on
35 mm dishes. A wound was made in each cell monolayer.
Images were captured on time 0 and 24 h. Cell migration
distance was determined by subtracting values obtained at
0 h from 24 h. Migration distances were expressed as
percentages over control values.
Intrasplenic injection-induced liver metastases
Mouse injections were performed in accordance with
the NIH Guide for the Care and Use of Laboratory
Animals and approved by the Institutional Animal Care
and Use Committee of Cedars-Sinai Medical Center.
Briefly, Six-week-old female nude (nu/nu) mice (Jackson
Laboratories) were anesthetized (by IP injecting Ketamine
[75 mg/kg] and Dexmedetomidine [0.5 mg/kg] ). Carpro-
fen at 5.0 mg/kg were injected subcutaneously after
anesthesia induction and prior to performing surgery. The
abdomen was disinfected with Iodine and alcohol swab
and a small midline incision was made. The spleen is exte-
riorized and 10 cells in 50 μ l PBS were injected. After
injection, the spleen was then returned to the abdomen
cavity. The abdomen wall was closed using absorbable
suture (Dexon) in a continuous suture pattern. The skin
will be closed using a 6–0 nylon suture (Dexon) in an
interupted suture patter. 0.1 mg/kg buprenorphine will be
injected subcutaneously after operation. 1.0 mg/kg atipa-
mezole will be injected ip to reverse dexmedetomidine.
Animals were kept in a clean cage. The research staff gave
warm fluid subcutaneously (1 ml/100 g body weight) and
also put a petri dish with water soaked food on the cage
floor. After one week, animals were anesthetized with
isoflurane in a desiccator jar in the appropriate fume
hood. The sutures on the body wall were removed. Mice
were monitored daily for adverse effects. Six weeks after
intrasplenic injection, the mice were sacrificed and aut-
opsy performed to check for formation of liver metastases.
Statistical analysis
All results were expressed as mean ± SD. Two-group com-
parison was assessed by nonpaired, two tailed Student’s t
test. The difference between multiple groups was assessed
by ANOVA.
Results
1. FoxM1 and PTTG1 are concordantly expressed in
colorectal cancer
Multiple microarray datasets were analyzed to determine
the correlation between FoxM1 and PTTG1 mRNA levels.
The results consistently demonstrated that the mRNA
levels of PTTG1 and FOXM1 are highly correlated. The
levels of correlation (R = 0.68 ~ 0.89, p = 2.1E-226 ~ 9.6E-
86) for seven datasets are shown in Fig. 1a, which include
three colon cancer datasets (GSE2109, n = 315; GSE41258,
n = 388; GSE39582, n = 564), one breast cancer dataset
(GSE3494, n = 251), one glioma dataset (TCGA, n = 403),
one ovarian cancer dataset (GSE9891, n = 285) and one
neuroblastoma dataset (GSE45547, n = 649). We fur-
ther analyzed GSE2109 dataset to determine whether
known FoxM1 targeted genes exhibited concordant
expression pattern with FoxM1. In the top 15 concor-
dantly expressed genes, 8 are known FoxM1 targets,
including CCNB2, BUB1, CDC20, CCNB1, BIRC5,
BUB1B, CEP55 and CENPF. PTTG1 was ranked as the
fifth (R = 0.79, P = 6.9E-65) gene concordantly expressed
with FoxM1 (Fig. 1b), suggesting that PTTG1 is a poten-
tial target of FoxM1.
We also analyzed microarray dataset derived from BT-
20 breast cancer cells transfected with mock or FoxM1
siRNA (GSE2222) [36]. Forty nine genes were differen-
tially expressed between mock and FoxM1 siRNA trans-
fected cells (FDR < 0.05). Centrosomal protein 55 kDa
(CEP55), a known target gene of FoxM1, was down-
regulated 1.5 folds (p = 2.95E-05) in the FoxM1 siRNA
transfected cells. PTTG1 was down-regulated 1.8 folds (p
= 7.40E-05, Fig. 1c).
2. FoxM1 regulates the transcription and expression of
PTTG1
To determine whether FoxM1 modulates PTTG1 ex-
pression in colorectal cancer cells, we first examined
FoxM1 expression in 61 colorectal cancer cell lines using
microarray data derived from CCLE (Cancer Cell Line
Encyclopedia) [37]. The results indicate that most colo-
rectal cancer cell lines, including SW620 and HCT116,
express abundant FoxM1 mRNA (Additional file 2).
SW620 and HCT116 colorectal cancer cells were then
transfected with mock or FoxM1 siRNA. As shown in
Fig. 2a and b, transfection of FoxM1 siRNA suppressed
FoxM1 mRNA by ~87 % in HCT116 and ~70 % in
SW620 cells, and reduced PTTG1 mRNA by ~57 % in
HCT116 and ~36 % in SW620 cells, respectively. As a
result, FoxM1 protein level was reduced by ~99 % in
SW620 and ~63 % in HCT116 cells, and PTTG1 protein
expression decreased ~75 % in SW620 and ~40 % in
HCT116 cells, respectively (Fig. 2c and d). After trans-
fected with FoxM1 expression plasmids, the FoxM1
mRNA levels increased 12.23 fold in SW620 and 15.34
fold in HCT116 cells. The protein levels increased 3.67
folds in SW620 and 4.97 folds in HCT116 cells (Fig. 2c
and d). Over-expressed FoxM1 enhanced PTTG1
mRNA expression 3.22 folds and protein expression
1.43 folds in SW620 cells. Similar results (3.4 folds in
mRNA levels and 2.23 folds in protein levels) were ob-
tained in HCT116 cells (Fig. 2c and d). These results sug-
gest that FoxM1 indeed enhances PTTG1 transcription.
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3. FoxM1 binds to PTTG1 promoter
GeneQuest (Lasergene7.1) identified two potential
FoxM1-binding motifs, i.e. 5’-TATTTAT-3’and 5’-TAAA-
TAA-3’, located at −391 to −385 (1st site) and −359 to
−353 bp (2nd site) upstream of the translation initiation
site of PTTG1. Four PTTG1 promoter fragments cover-
ing 5’ upstream −1300, −900, −600 and −300 to +50 bp
were cloned into pGL3-basic luciferase plasmid. These
luciferase plasmids were co-transfected with FoxM1 or
control plasmid into colorectal cancer cells, and pro-
moter activity measured. As shown in Fig. 3a, all three
constructs induced transcriptional activities in response
to FoxM1 co-transfection in both cell lines. Similarly,
the luciferase plasmids were co-transfected with FoxM1
siRNA and corresponding control siRNA. The −1300,
−900 and −600 bp PTTG1 promoter activity was signifi-
cantly inhibited after co-transfected with FoxM1 siRNA
(Fig. 3a), suggesting that the FoxM1 responsive elements
locate between −600 to −300 bp region. We mutated the
FoxM1 binding sites of the –600 bp PTTG1 promoter in
the pGL3-basic plasmid and evaluated FoxM1 effects on
the mutated promoters. Mutation of 1st site leads to
reduction of 45 % of promoter activity. Mutation of 2nd
site leads to reduction of 34 %. Loss of both FoxM1
A C
B
Fig. 1 Correlation between FoxM1 and PTTG1 expression in colorectal cancer. a FoxM1 closely correlates to PTTG1 expression in 7 tumor microarray
datasets (upper table). Expression levels of FoxM1 and PTTG1 were obtained from a colon cancer microarray dataset (GSE2019, n = 315) and plotted in
lower figure. b The top 15 genes associated with FoxM1 expression in GSE2019 dataset. Known FoxM1 target genes were bolded. PTTG1 is ranked as
fifth. c Differentially expressed genes in BT-20 breast cancer cells transfected with mock or FoxM1 siRNA. The microarray data were standardized (shift
genes to means of zero and scale to standard deviation of one). Two-way Hierarchical Clustering was performed. The heat map (upper figure) shows
that 49 genes were differentially expressed including CEP55 and PTTG1. The lower figure indicated that the PTTG1 is statistically down-regulated by
FoxM1 knock-down
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binding sites leads to a reduction of 77 % promoter ac-
tivity when co-transfected with FoxM1 (Fig. 3b).
Next, we carried out a biotin-streptavidin EMSA to
verify the interaction between FoxM1 protein and hepta-
mer motifs at −391 to −385 and −359 to −353 bp of the
PTTG1 promoter. A 60 bp biotin-labeled probe contain-
ing two FoxM1-binding motifs on the human PTTG1
promoter was synthesized and the binding with FoxM1
was examined. As shown in Fig. 3c, the incubation of
labeled probe and FoxM1 protein resulted in the appear-
ance of a DNA-protein complex (lane 2). The DNA-
protein binding was abolished by adding cold competi-
tive probe (lane 3), strongly inhibited by adding the
60 bp mutant probe with the first site (−391 to −385 bp)
mutated (lane 5) and the 20 bp mutant oligonucleotide
with the first site mutated (lane 6), and slightly reduced
by adding the 20 bp mutant oligonucleotide with the
second site (−359 to −353 bp) mutated (lane 7). We also
used double sites mutated probe as negative control,
which exhibited diminished DNA-protein interaction
band (lane 4). These results indicated that both
FoxM1-binding sites in the PTTG promoter partici-
pates in PTTG1 transcriptional regulation by FoxM1,
and directly bind FoxM1 protein. However, we failed
to generate supershifts when adding FoxM1 antibody
to the EMSA reaction, which might be due to lack of
a qualified FoxM1 antibody for EMSA.
As FoxM1 protein is in a native state in EMSA assay
but in a denatured state in ChIP, FoxM1 antibody not suit-
able for EMSA may be able to recognize the denatured
FoxM1 in the ChIP experiments. We then performed
ChIP assay to determine whether FoxM1 binding to
PTTG1 promoter. About 107 HCT116 cells were fixed
and chromatin DNA sonicated into about 200–500 bp
fragments. Equal amounts of chromatin DNA were incu-
bated separately with IgG, FoxM1 antibody, histone H3
antibody or water. The captured chromatin DNA frag-
ments were analyzed using PCR by three primer pairs tar-
geting different region (PTTG1 -391 to −353, PTTG1
exon2, VEGF promoter). As shown in Fig. 3c, DNA
enriched by FoxM1 antibody was positive for primers
targeting PTTG1 promoter −391 to −353 bp region, indi-
cating that FoxM1 specifically binds to the PTTG1 pro-
moter. Primers targeting PTTG1 exon2 were used as a
negative control, which produced a positive amplification
in the input sample and a negative amplification in the
FoxM1 ChIP sample. Primers targeting VEGF promoter
were used as a positive control and produced a positive
A B
C D
Fig. 2 FoxM1 induces PTTG1 mRNA and protein expression in colon cancer cells. FoxM1 siRNA suppressed PTTG1 mRNA expression. SW620 (a)
and HCT116 (b) cells were transfected with negative control siRNA (Con), FoxM1 siRNA (siFoxM1), negative control pcDNA3.1 (Con) or FoxM1
plasmid (FoxM1), respectively. FoxM1 and PTTG1 mRNA levels were detected by real-time PCR; results were normalized with controls and
expressed as mean ± SD from triplicate assays. FoxM1 siRNA inhibited, and over-expression increased PTTG1 protein expression. SW620 (c) and
HCT116 (d) cells were transfected with negative control siRNA (Con), FoxM1 siRNA (siFoxM1), negative control pcDNA3.1 (Con) or FoxM1 plasmid
(FoxM1), respectively. FoxM1 and PTTG1 protein levels were measured by western blot. All western blot experiments were repeated three times.
Results of a representative experiment are shown. *p < 0.05, **p < 0.01, ***p < 0.001
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signal in both input and FoxM1 ChIP sample. As the two
FoxM1 binding sites are only 30 bp away from each other,
we are not able to discriminate the binding difference of
FoxM1.
4. Attenuate PTTG1 and FoxM1 expression suppress
migration, invasion and metastasis of colon cancer cells
High PTTG1 is associated with invasiveness [38]. In vitro
cell migration and invasion assays indicated that PTTG1
knock-out HCT116 cells exhibited impaired migration and
invasion (Fig. 4a and b). The migration of PTTG1−/−
HCT116 cells decreased about 80.6 % (P < 0.001) and the
invasion ability decreased about 86.8 % (P < 0.001) com-
pared with those of PTTG1+/+ control cells (Fig. 4a and b).
In wound-healing assay, PTTG1 knock-out caused 34.3 %
(P < 0.05) decrease in cell migration compared with those
of PTTG1 wild-type HCT116 cells (Fig. 4c). Transfection
of FoxM1 siRNA in HCT116 cells also resulted in a signifi-
cant decrease of migration (78.4 %; P < 0.001) and invasion
(74 %; P < 0.001), compared with cells transfected with
siRNA control (Fig. 4a and b). We also investigated whether
forced expression of FoxM1 would increase cell migration
and invasion. Surprisingly, transfection of FoxM1 plasmids
did not further enhance the migration and invasion of WT
A
C
B
D
Fig. 3 FoxM1 binds to and activates PTTG1 promoter. a Luciferase reporter assay. SW620 cells were transfected with pGL3-Basic,
pGL3-PTTG1 –1300, −900, −600 or −300/+50 reporter plasmids and co-transfected with pcDNA3.1 control, pcDNA3.1-FoxM1 plasmid
(FoxM1), siRNA control or FoxM1 siRNA (siFoxM1), together with Renilla reporter vector. Cells were harvested after 24 h and luciferase
activities were examined. After normalizing to Renilla, results are expressed as mean ± SD. Assays were performed in triplicate and
experiments were repeated three times. Results of a representative experiment are shown. *p < 0.05, **p < 0.01, ***p < 0.001. b FoxM1
binding sites on the -600 bp PTTG1 promoter (pGL3-PTTG1-600) are mutated and these mutants are co-transfected with FoxM1 to
evaluate effects of FoxM1 on the activity of mutated promoter (1st site: −391 to −385, 2nd site: −359 to −353 bp of TSS). c Biotin-streptavidin EMSA.
Representative EMSA shows the bindings of FoxM1 protein with Biotin-Probe in lane 2 (biotin-labeled 60 bp probe, containing both −391 to −385 and
−359 to −353 bp wild type FoxM1-binding PTTG1 promoter motifs), with Biotin-dmProbe in lane 4 (biotin-labeled 60 bp probe, containing both −391
to −385 and −359 to −353 bp mutant FoxM1-binding sites) and with 1st site mProbe (biotin-labeled 60 bp probe with −391 to −385 bp mutant
FoxM1-binding site, lane 5). Competition assays were performed using a 100-folds excess of cold probe (unlabeled 60 bp wild type probe, lane 3), 1st
site oligo (unlabeled 22 bp oligonucleotide only containing −391 to −385 bp wild type FoxM1-binding motif, lane 6) and 2nd site oligo (unlabeled
25 bp oligonucleotide only containing −359 to −353 bp wild type FoxM1-binding motif, lane 7). d ChIP assay showing specific endogenous FoxM1
binding to the human PTTG1 promoter. About 500 bp length chromatin DNA in HCT116 cells were immunoprecipitated with FoxM1 antibody,
negative control IgG, positive control histone H3 antibody (H3) and water blank control as indicated. Enrichment of chromatins was obtained with
primers targeting PTTG1 promoter but not with primers targeting PTTG1 exon 2. The experiment was repeated twice. As VEGF is a known target of
FoxM1, primers targeting VEGF promoter were included as a positive control
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Fig. 4 PTTG1 knock-out and FoxM1 knock-down suppress colon cancer cell migration, invasion and liver metastasis. a, b In vitro migration (a) and i
nvasion (b) assays in HCT116 cells. Left panel: representative migration and invasion photographs of PTTG1+/+, PTTG1−/−, control siRNA- and FoxM1
siRNA (siFoxM1)-transfected cells. Right panel: quantification of migrated and invaded cells per field at × 40 magnification. Experiments were repeated
three times. c Wound-healing assay in FoxM1 over expressing PTTG1+/+ and PTTG1−/− HCT116 cells. The cells were allowed to form monolayers in a
6-well plate. A wound was created by a pipette tip. The healing of the wounds was monitored under microscope. Pictures were taken at different
time points. Left panel: representative migration images of FoxM1 over expressing PTTG1+/+ and PTTG1−/− HCT116 cells. Right panel: wound
closure percentage was determined by subtracting values obtained at 0 h from 24 h. Experiments were repeated three times. d FoxM1 over
expressing PTTG1+/+ or PTTG1−/− HCT116 cells were injected into spleen to induce liver metastasis. Left panel: representative images of metastatic liver
tumor derived from mice injected with control cells and FoxM1 overexpressing cells. Histochemistry and western blots indicated that the metastatic foci
are derived from the injected cells and FoxM1 was overexpressed in the FoxM1 overexpressing group. Right panel: summary of metastatic liver foci
numbers and liver weight. All data above are presented as the mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001
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or PTTG1−/− HCT116 cells (Data not shown), which could
due to a high baseline expression of FoxM1 in the tested
cells.
To investigate the role of PTTG1 and FoxM1 in colon
cancer metastasis, we stably expressed FoxM1 in PTTG1
+/+ and PTTG1−/− HCT116 cells, and implanted these
cells into the spleen of nude mice to induce liver metasta-
ses. Mice were killed 6 weeks after intrasplenic injection.
In the PTTG1+/+ control group without FoxM1 over ex-
pression, 8 out of 10 developed liver tumors (15–34 meta-
static loci). The PTTG1−/− control group without FoxM1
over expression, 5 out of 10 developed live metastases
(4–14 metastatic loci). All 10 mice (100 %) in the
PTTG1+/+ FoxM1 overexpressing group developed liver
tumors (35–58 metastatic loci), while 4 out of 10 mice
in the PTTG1−/− FoxM1 group exhibited small liver tu-
mors (5–13 metastatic loci). The overall liver weights
in the PTTG1−/− implanted mice were much less than
these derived from PTTG1+/+ group. Overexpression of
FoxM1 enhanced liver metastases of the PTTG1+/+
HCT116 cells but not these of the PTTG1−/− cells.
Histochemistry indicated that the metastatic foci (marked
by arrow head) are derived from colorectal cancer (Fig. 4d).
Western blots confirmed the enhanced FoxM1 expression
in the metastatic foci derived from FoxM1 stably
expressed cells. The results support the above in vitro cell
migration and invasion findings and indicate that PTTG1
knock out attenuates FoxM1-induced colon cancer
metastasis.
5. FoxM1-PTTG1 regulates Wnt antagonist DKK1
Using Illumina HumanHT-12_V4 microarrays, we com-
pared the gene expression profiles of PTTG1+/+ and
PTTG1−/− HCT116 cells (GSE58863). We identified 662
significantly differentially expressed genes (FDR < 0.05,
Fig. 5a). We randomly selected 40 genes for validation
using qPCR, and found that 37 genes were consistent up
or down regulated between qPCR and microarray analysis
(Fig. 5a), including 32 up-regulated genes (including
SEMA3A, TP53I3, CDKN1A, CD33, CALB2, DLG4, SGK,
PIK3R1, ABCA1, DKK1, BTG2, TP53INP1, ACSS2,
IL11RA, RTN1, GSTM1, GSN, SCN9A,THBS1, LYL1,
TAGLN, OLFM1, PHF1, CSPG4, MSRB3, PMP22,
TGFBR3, FHL1, IDS, TLR5, IL4R, and BAG3) and 5
down-regulated genes (including CEBPB, TRIB3, EREG,
DDIT4 and MAL2).
To obtain insight into the role of PTTG1 in colon cancer
cells, we performed ingenuity pathway analysis (IPA) using
the differentially expressed genes present in PTTG1−/−
HCT116 cell. The network analysis highlighted an
enhancement of TP53 signaling pathway. It was predicted
that the enhanced Tp53 further modulates STAT3 to
attenuate CTNNB1, a key component of Wnt pathway
(Fig. 5b). As DKK1, an inhibitor of the Wnt signaling
pathway, is induced by p53 [39], we seek to determine
whether DKK1 mediates the FoxM1 and PTTG1 effects.
DKK1 expression was examined in HCT116 cells when
FoxM1 or PTTG1 are over-expressed or knock-down.
The DKK1 mRNA and protein levels decreased ~67 %
and ~50 % (Fig. 5c, column 2), respectively, in response to
PTTG1 over-expression and increased over 5.28 folds and
2.5 folds (Fig. 5c, column 3), respectively, as a result of
PTTG1 knock-down. Meanwhile, the DKK1 mRNA and
protein levels reduced ~71 % and ~45 % under FoxM1
over-expression (Fig. 5d, column 2) and increased 4.1
-folds and 1.8 folds in response to FoxM1 knock-down
(Fig. 5d, column 3).
Discussion
Bioinformatic analyses indicated that FoxM1 and PTTG1
are concordantly expressed in human colorectal cancer
tissues, suggesting PTTG1 is a potential target of FoxM1.
We further presented evidence that FoxM1 activates
PTTG1 transcription through binding to PTTG1 pro-
moter. Our results indicated that forced over expression
of FoxM1 up-regulates PTTG1. FoxM1 binds to DNA
with a preference for a consensus 5’-A-T/C-AAA-T/C-
AA-3’ recognition sequence [40] and there are two po-
tential FoxM1 binding sites on the PTTG1 promoter.
Luciferase reporter assay confirmed the transcriptional
regulatory activity of FoxM1 on PTTG1 promoter.
EMSA indicated that FoxM1 binds to both FoxM1
binding sites on the PTTG1 promoter. The binding of
FoxM1 on the PTTG1 promoter is confirmed by ChIP
assay.
The functions of FoxM1 and PTTG1 in regulating cell
migration and invasion were surveyed. Boyden chamber
assay indicated that FoxM1 and PTTG1 siRNAs attenu-
ated migration and invasion of HCT116 and SW620
colorectal cancer cells. Wound-healing assay further
suggested that PTTG1 mediates FoxM1 effects in regu-
lating cell migration. The in vivo tumor xenografts also
provided evidence that PTTG1 participates in the
FoxM1-mediated liver metastases of colon cancer.
FoxM1 plays a central role in regulating many cellular
functions, including cell proliferation, cell survival, and
immortalization, and is critical to carcinogenesis and
metastasis of cancers, including gastric cancer, colorectal
cancer, pancreatic cancer, breast cancer, non-Hodgkin’s
lymphoma, glioma and malignant peripheral nerve sheath
tumors [26, 27, 41, 42]. Over-expression of FoxM1 in-
volved in cell-cycle progression, invasion and angiogen-
esis, epithelial-to-mesenchymal transition (EMT) directly
through up-regulating of its target genes, e.g. CDC25B,
CCNB1, AURKB, PLK1, CENPA, CENPB, MYC, SKP2,
MMP2 and VEGF. In present study, we identified PTTG1
as a FoxM1 target gene in colon cancer, which provides a
mechanism of FoxM1 involved in the metastasis of
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Fig. 5 Genes regulated by PTTG1. a Differentially expressed genes in WT and PTTG1−/− HCT116 cells. Upper: heat map of 662 differentially expressed
genes (FDR < 0.05) between WT and PTTG1−/− HCT116 cells. Lower: 37 out of 40 genes were consistent between microarray and qPCR. Results of
qPCR were calculated using the ΔΔCt method with GAPDH as an internal control. b Signaling network analysis of 662 differentially expressed genes
revealed a network involve p53 and CTNNB1. c PTTG1 regulates DKK1 expression. HCT116 cells were transfected with pcDNA3.1 and negative control
siRNA (control), pcDNA3.1 and PTTG1 siRNA (siPTTG1), control siRNA and pcDNA3.1-PTTG1 (PTTG1), respectively. Left: FoxM1, PTTG1 and DKK1 mRNA
levels were detected by real-time qPCR. Right: FoxM1, PTTG1 and DKK1 protein levels were detected by western blot. d FoxM1 regulates PTTG1 and
DKK1 expression. HCT116 cells were transfected with pcDNA3.1 and negative control siRNA (control), pcDNA3.1 and FoxM1 siRNA (siFoxM1), control
siRNA and pcDNA3.1-FoxM1 (FoxM1), respectively. Left: FoxM1, PTTG1 and DKK1 mRNA levels were detected by qPCR. Right: FoxM1, PTTG1 and DKK1
protein levels were detected by western blot. All qPCR were performed in triplicates and normalized to GAPDH. β-actin was used as an internal control
for western blot. Results from three experiments were expressed as mean ± SD. Western blot experiments were repeated three times. Results
of a representative experiment are shown. *p < 0.05, **p < 0.01, ***p < 0.001
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malignances [26, 43–45]. We discovered that FoxM1 dir-
ectly bound to the promoter region of PTTG1 gene,
which is inconsistent with the previous report [46]. We
also provide evidence showing that FoxM1 activates
PTTG1 transcription. PTTG1 is required for FoxM1 to
promote colorectal cancer cell migration and invasion.
Identification of PTTG1 as a FoxM1 target gene provides
further evidence linking FoxM1 function to carcinogenesis
and progression.
Up-regulation of PTTG1 has been correlated with ag-
gressive disease and poor prognosis in hepatocellular
carcinoma, prostate cancer, esophageal cancer, glioma,
thyroid cancer and colorectal cancer [13–19]. Previous
studies showed that PTTG1 was directly regulated by es-
trogen, insulin, basic fibroblast growth factor, epidermal
growth factor, β-catenin/transcription factor, Rb/E2F1
pathways, STAT3, etc., and consequently involved in mul-
tiple steps of tumor progression including tumorigenesis,
invasiveness, metastasis, and angiogenesis [11, 20–24, 47].
Our study demonstrated a novel FoxM1-PTTG1 relation
and implied a new mechanism of PTTG1 involving tumor
progression.
DKK1, as a Wnt antagonist, shows wide and complex
effects on cell proliferation and differentiation. The dis-
tinct effects of DKK1 seem to depend on the cell type,
which agrees with the different effects of Wnt/β-catenin
signaling [48]. In colon cancer, DKK1 was found down-
regulated, indicating the loss of a negative feedback con-
trol of the Wnt/β-catenin pathway in this neoplasia [49].
Our microarray data showed that DKK1 was up-regulated
in PTTG1−/− cells and the further in vitro assays indicated
that DKK1 was down-regulated by over expressing either
FoxM1 or PTTG1. Our results suggest that abnormal up-
regulated FoxM1-PTTG1 pathway may promote colon
cancer through suppressing DKK1 and thereby enhancing
the Wnt pathway. In addition, the IPA analysis of PTTG1-
regulated genes indicated an enhanced TP53 pathway,
which are consistent with previous report [50]. DKK1 has
been found induced by TP53 [39], which suggested that
FoxM1-PTTG1 pathway may regulate DKK1 through
modulating TP53 pathway. PTTG1 has been shown to
be a direct target gene of β-catenin [51]. PTTG1 may
therefore provide a positive feedback to enhance its
own transcription by enhancing WNT pathway through
suppressing DKK1.
In summary, we provide evidence that (1) FoxM1
regulates PTTG1 transcription through binding to
PTTG1 promoter; (2) FoxM1 or PTTG1 knockdown at-
tenuate colorectal cancer cell migration, invasion and
metastasis; (3) FoxM1 activates PTTG1, which subse-
quently suppresses Wnt antagonist, DKK1. These find-
ings expand our knowledge on regulatory mechanisms
underlying tumor PTTG1 abundance. In the ongoing
search for molecular points of therapeutic intervention
for various malignancies, both PTTG1 and FoxM1 have
been considered as promising and attractive targets for
cancer therapy. The FoxM1-PTTG1 pathway we have
identified will help to define the proper therapeutic
window in which targeting FoxM1 or PTTG1 can
achieve clinical benefits. However, more studies are
needed to further understand the precise mechanisms
of the FoxM1 and PTTG1 involved in different cellular
contexts and tumor types, and in response to different
types of damage.
Conclusions
The results indicate that PTTG1 is a FoxM1 targeted gene.
FoxM1 binds to PTTG1 promoter to promote PTTG1
transcription, and FoxM1-PTTG1 pathway promotes colo-
rectal cancer migration and invasion.
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